Icahn attacks Amylin management
This article was originally published in Scrip
Executive Summary
The public spat between Amylin Pharmaceuticals and its dissident shareholders continued unabated yesterday, with Carl Icahn lambasting the firm's apparent lack of communication and opposition to his management suggestions.